Literature DB >> 23538200

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Don Husereau1, Michael Drummond, Stavros Petrou, Chris Carswell, David Moher, Dan Greenberg, Federico Augustovski, Andrew H Briggs, Josephine Mauskopf, Elizabeth Loder.   

Abstract

Economic evaluations of health interventions pose a particular challenge for reporting. There is also a need to consolidate and update existing guidelines and promote their use in a user friendly manner. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement is an attempt to consolidate and update previous health economic evaluation guidelines efforts into one current, useful reporting guidance. The primary audiences for the CHEERS statement are researchers reporting economic evaluations and the editors and peer reviewers assessing them for publication. The need for new reporting guidance was identified by a survey of medical editors. A list of possible items based on a systematic review was created. A two round, modified Delphi panel consisting of representatives from academia, clinical practice, industry, government, and the editorial community was conducted. Out of 44 candidate items, 24 items and accompanying recommendations were developed. The recommendations are contained in a user friendly, 24 item checklist. A copy of the statement, accompanying checklist, and this report can be found on the ISPOR Health Economic Evaluations Publication Guidelines Task Force website: (www.ispor.org/TaskForces/EconomicPubGuidelines.asp). We hope CHEERS will lead to better reporting, and ultimately, better health decisions. To facilitate dissemination and uptake, the CHEERS statement is being co-published across 10 health economics and medical journals. We encourage other journals and groups, to endorse CHEERS. The author team plans to review the checklist for an update in five years.
Copyright © 2013. Published by Elsevier Inc.

Mesh:

Year:  2013        PMID: 23538200     DOI: 10.1016/j.jval.2013.02.010

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  187 in total

1.  Cost-Effectiveness of Drug Treatment for Chinese Patients With Stage I Hypertension According to the 2017 Hypertension Clinical Practice Guidelines.

Authors:  Yan-Feng Zhou; Na Liu; Pei Wang; Jae Jeong Yang; Xing-Yue Song; Xiong-Fei Pan; Xiaomin Zhang; Meian He; Honglan Li; Yu-Tang Gao; Yong-Bing Xiang; Tangchun Wu; Danxia Yu; An Pan
Journal:  Hypertension       Date:  2020-07-27       Impact factor: 10.190

2.  Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.

Authors:  Verin Lertjanyakun; Nathorn Chaiyakunapruk; Susumu Kunisawa; Yuichi Imanaka
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

3.  Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial.

Authors:  Wen Wan; M Reza Skandari; Alexa Minc; Aviva G Nathan; Parmida Zarei; Aaron N Winn; Michael O'Grady; Elbert S Huang
Journal:  Med Decis Making       Date:  2018-11       Impact factor: 2.583

4.  Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.

Authors:  Wen Wan; M Reza Skandari; Alexa Minc; Aviva G Nathan; Aaron Winn; Parmida Zarei; Michael O'Grady; Elbert S Huang
Journal:  Diabetes Care       Date:  2018-04-12       Impact factor: 19.112

5.  Added value of cost-utility analysis in simple diagnostic studies of accuracy: (18)F-fluoromethylcholine PET/CT in prostate cancer staging.

Authors:  Oke Gerke; Mads H Poulsen; Poul Flemming Høilund-Carlsen
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

6.  Cost-effectiveness of Shared Telemedicine Appointments in Young Adults With T1D: CoYoT1 Trial.

Authors:  Wen Wan; Aviva G Nathan; M Reza Skandari; Parmida Zarei; Mark W Reid; Jennifer K Raymond; Elbert S Huang
Journal:  Diabetes Care       Date:  2019-06-12       Impact factor: 19.112

7.  Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence.

Authors:  Ilaria Loperto; Andrea Simonetti; Antonio Nardone; Maria Triassi
Journal:  Hum Vaccin Immunother       Date:  2019-03-25       Impact factor: 3.452

8.  Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer.

Authors:  W W L Wong; M Zargar; S R Berry; Y J Ko; M Riesco-Martínez; K K W Chan
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

9.  Costs and outcomes for individuals with psychosis prior to hospital admission and following discharge in Bulgaria.

Authors:  Desislava Ignatova; Maria Kamusheva; Guenka Petrova; Georgi Onchev
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-03-30       Impact factor: 4.328

10.  Cost Utility Analysis of Topical Steroids Compared With Dietary Elimination for Treatment of Eosinophilic Esophagitis.

Authors:  Cary C Cotton; Daniel Erim; Swathi Eluri; Sarah H Palmer; Daniel J Green; W Asher Wolf; Thomas M Runge; Stephanie Wheeler; Nicholas J Shaheen; Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.